-
公开(公告)号：US07001598B2
公开(公告)日：2006-02-21
申请号：US09931402
申请日：2001-08-16
IPC分类号： A61K49/00 , A61K39/395
CPC分类号： A61K38/191 , A61K39/395 , A61K2039/505 , C07K14/525 , C07K14/715 , C07K16/2866 , C07K2317/24 , C07K2317/52 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/30 , Y10S424/809 , A61K2300/00
摘要： This invention relates to compositions and methods useful for treating or reducing the advancement, severity or effects of neoplasia by the administration of at least two or more lymphotoxin beta receptor (LT-β receptor) activating agents where at least one LT-β receptor activating agent is an anti-LT-β receptor antibody.
-
2.发明申请公开(公告)号：US20090123421A1
公开(公告)日：2009-05-14
申请号：US12262794
申请日：2008-10-31
IPC分类号： A61K38/21 , A61K39/395 , C12Q1/02 , C07K16/18 , A61K38/16
CPC分类号： A61K38/191 , A61K39/395 , A61K2039/505 , C07K14/525 , C07K14/715 , C07K16/2866 , C07K2317/24 , C07K2317/52 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/30 , Y10S424/809 , A61K2300/00
摘要： This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-a and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-β receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-β receptor which act as lymphotoxin-β receptor activating agents alone or in combination with other lymphotoxin-β receptor activating agents either in the presence or absence of lymphotoxin-a/β complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-β receptor antibodies either alone or in the presence of other lymphotoxin-β receptor activating agents to potentiate tumor cell cytotoxicity.
摘要翻译： 本发明涉及用于激活LT-β受体信号传导的组合物和方法，其又引起对肿瘤细胞的有效的抗增殖作用。 更具体地，本发明涉及在淋巴毒素-a和淋巴毒素-β的多个亚基之间形成的淋巴毒素异聚体复合物，其在淋巴毒素-β受体活化剂存在下诱导对肿瘤细胞的细胞毒性作用。 也在本发明范围内的是针对淋巴毒素-β受体的抗体，其单独或与其它淋巴毒素-β受体活化剂组合起作用，即在存在或不存在淋巴毒素-α/β复合物的情况下作为淋巴毒素-β受体活化剂 。 提供了选择这种抗体的筛选方法。 本发明还涉及使用交联的抗淋巴毒素-β受体抗体单独或在其它淋巴毒素-β受体活化剂存在下增强肿瘤细胞毒性的组合物和方法。
-
公开(公告)号：US07459537B2
公开(公告)日：2008-12-02
申请号：US11185373
申请日：2005-07-19
IPC分类号： C07K16/00
CPC分类号： A61K38/191 , A61K39/395 , A61K2039/505 , C07K14/525 , C07K14/715 , C07K16/2866 , C07K2317/24 , C07K2317/52 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/30 , Y10S424/809 , A61K2300/00
摘要： This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-α and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-β receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-β receptor which act as lymphotoxin-β receptor activating agents alone or in combination with other lymphotoxin-β receptor activating agents either in the presence or absence of lymphotoxin-α/β complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-β receptor antibodies either alone or in the presence of other lymphotoxin-β receptor activating agents to potentiate tumor cell cytotoxicity.
摘要翻译： 本发明涉及用于激活LT-β受体信号传导的组合物和方法，其又引起对肿瘤细胞的有效的抗增殖作用。 更具体地，本发明涉及在淋巴毒素-α与淋巴毒素-β的多个亚基之间形成的淋巴毒素异聚体复合物，其在淋巴毒素-β受体活化剂存在下诱导对肿瘤细胞的细胞毒性作用。 也在本发明范围内的是针对淋巴毒素-β受体的抗体，其单独或与其它淋巴毒素-β受体活化剂组合起作用于淋巴毒素-α-β复合物存在或不存在的淋巴毒素-β受体活化剂 。 提供了选择这种抗体的筛选方法。 本发明还涉及使用交联的抗淋巴毒素-β受体抗体单独或在其它淋巴毒素-β受体活化剂存在下增强肿瘤细胞毒性的组合物和方法。
-
4.发明授权Lymphotoxin-&agr;/&bgr; complexes and anti-lympotoxin-&bgr; receptor antibodies as anti-tumor agents 失效淋巴毒素-α/β复合物和抗淋巴毒素-β受体抗体作为抗肿瘤剂公开(公告)号：US06312691B1
公开(公告)日：2001-11-06
申请号：US08875560
申请日：1998-06-05
IPC分类号： A61K39395
CPC分类号： A61K38/191 , A61K39/395 , A61K2039/505 , C07K14/525 , C07K14/715 , C07K16/2866 , C07K2317/24 , C07K2317/52 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/30 , Y10S424/809 , A61K2300/00
摘要： This invention relates to compositions and methods useful for activating LT-&bgr; receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-&agr; and multiple subunits of lymphotoxin-&bgr;, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-&bgr; receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-&bgr; receptor which act as lymphotoxin-&bgr; receptor activating agents alone or in combination with other lymphotoxin-&bgr; receptor activating agents either in the presence or absence of lymphotoxin-&agr;/&bgr; complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-&bgr; receptor antibodies either alone or in the presence of other lymphotoxin-&bgr; receptor activating agents to potentiate tumor cell cytotoxicity.
摘要翻译： 本发明涉及用于激活LT-β受体信号传导的组合物和方法，其又引起对肿瘤细胞的有效的抗增殖作用。 更具体地，本发明涉及在淋巴毒素-α与淋巴毒素-β的多个亚基之间形成的淋巴毒素异聚体复合物，其在淋巴毒素-β受体活化剂存在下诱导对肿瘤细胞的细胞毒性作用。 也在本发明范围内的是针对淋巴毒素-β受体的抗体，其单独或与其它淋巴毒素-β受体活化剂组合起作用，即在存在或不存在淋巴毒素-α/β复合物的情况下作为淋巴毒素-β受体活化剂 。 提供了选择这种抗体的筛选方法。 本发明还涉及使用交联的抗淋巴毒素-β受体抗体单独或在其它淋巴毒素-β受体活化剂存在下增强肿瘤细胞毒性的组合物和方法。
-
5.发明授权Soluble lymphotoxin-&bgr; receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease 有权可溶性淋巴毒素-β受体作为治疗TH-1细胞相关自身免疫疾病的治疗剂公开(公告)号：US06669941B1
公开(公告)日：2003-12-30
申请号：US09303262
申请日：1999-04-30
IPC分类号： A01N3800
CPC分类号： C07K14/7151 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising “lymphotoxin-&bgr; receptor blocking agents”, which block lymphotoxin-&bgr; receptor signalling. Lymphotoxin-&bgr; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&bgr; receptor extracellular domain that act as lymphotoxin-&bgr; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&bgr; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&bgr; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&bgr; receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号传导。 淋巴毒素-β受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体细胞外结构域的可溶性形式。 本发明还涉及针对作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体或其配体表面淋巴毒素的抗体的用途。 提供了一种选择可溶性受体，抗体和阻断LT-β受体信号传导的其他试剂的筛选方法。
-
6.发明授权Soluble lymphotoxin-&bgr; receptors as therapeutic agents for the treatment of immunological disease 失效可溶性淋巴毒素-β受体作为治疗免疫疾病的治疗剂公开(公告)号：US06403087B1
公开(公告)日：2002-06-11
申请号：US09000166
申请日：1998-06-08
IPC分类号： A61K39395
CPC分类号： C07K14/7151 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising “lymphotoxin-&bgr; receptor blocking agents”, which block lymphotoxin-&bgr; receptor signalling. Lymphotoxin-&bgr; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&bgr; receptor extracellular domain that act as lymphotoxin-&bgr; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&bgr; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&bgr; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&bgr; receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号传导。 淋巴毒素-β受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体细胞外结构域的可溶性形式。 本发明还涉及针对作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体或其配体表面淋巴毒素的抗体的用途。 提供了一种选择可溶性受体，抗体和阻断LT-β受体信号传导的其他试剂的筛选方法。
-
7.发明授权Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease 失效可溶性淋巴毒素-β受体和抗淋巴毒素受体和配体抗体作为治疗免疫疾病的治疗剂
公开(公告)号：US5925351A
公开(公告)日：1999-07-20
申请号：US505606
申请日：1995-07-21
IPC分类号： A61K38/00 , G01N33/566 , A61K31/00 , A61K38/17 , A61K38/19 , A61K39/00 , A61K39/395 , A61P1/00 , A61P1/04 , A61P3/00 , A61P3/10 , A61P15/00 , A61P17/00 , A61P17/06 , A61P21/00 , A61P25/00 , A61P27/00 , A61P27/02 , A61P29/00 , A61P37/00 , A61P37/02 , A61P37/06 , C07K14/715 , C07K16/24 , C07K16/28 , C12N15/02 , C12P21/08 , G01N33/00 , G01N33/577 , G01N33/68 , A61K38/16 , C07K16/00
CPC分类号： C07K14/7151 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , A61K2039/505 , A61K38/00 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising "lymphotoxin-.beta. receptor blocking agents", which block lymphotoxin-.beta. receptor signalling. Lymphotoxin-.beta. receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-.beta. receptor extracellular domain that act as lymphotoxin-.beta. receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-.beta. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-.beta. receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-.beta. receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号传导。 淋巴毒素-β受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体细胞外结构域的可溶形式。 本发明还涉及针对作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体或其配体表面淋巴毒素的抗体的用途。 提供了一种筛选可溶性受体，抗体和阻断LT-β受体信号传导的其他试剂的筛选方法。
-
8.发明授权Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders 有权抑制TH1细胞相关疾病中淋巴毒素-β受体信号传导的方法公开(公告)号：US08455445B2
公开(公告)日：2013-06-04
申请号：US13037092
申请日：2011-02-28
IPC分类号： A61K38/16 , A61P19/02 , C07K19/00 , C07K14/715
CPC分类号： C07K14/7151 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号传导。 淋巴毒素-β受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体细胞外结构域的可溶性形式。 本发明还涉及针对作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体或其配体表面淋巴毒素的抗体的用途。 提供了一种选择可溶性受体，抗体和阻断LT-β受体信号传导的其他试剂的筛选方法。
-
公开(公告)号：US07427403B2
公开(公告)日：2008-09-23
申请号：US10077406
申请日：2002-02-15
IPC分类号： A61K38/16 , A61K39/395 , C07K14/715 , C07K16/28
CPC分类号： C07K14/7151 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising “lymphotoxin-β receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号传导。 淋巴毒素-β受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体细胞外结构域的可溶性形式。 本发明还涉及针对作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体或其配体表面淋巴毒素的抗体的用途。 提供了一种选择可溶性受体，抗体和阻断LT-β受体信号传导的其他试剂的筛选方法。
-
10.发明申请SOLUBLE LYMPHOTOXIN-BETA RECEPTOR FUSION PROTEIN AND METHODS FOR INHIBITING LYMPHOTOXIN BETA-RECEPTOR SIGNALING 有权可溶性的LYMPHOTOXIN-BETA受体融合蛋白和抑制LYMPHOTOXINβ受体信号的方法公开(公告)号：US20110046073A1
公开(公告)日：2011-02-24
申请号：US11982415
申请日：2007-10-31
CPC分类号： C07K14/7151 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β.receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β.receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素 - 受体阻断剂”的组合物和方法，其阻断淋巴毒素 - 受体信号。 淋巴毒素 受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素 - bgr的淋巴毒素 - 受体细胞外结构域的可溶性形式。 受体阻断剂。 本发明还涉及针对作为淋巴毒素 - 蛋白的淋巴毒素 - 受体或其配体表面淋巴毒素的抗体的用途。 受体阻断剂。 用于选择可溶性受体，抗体和阻断LT-和bgr的其它试剂的新型筛选方法; 提供受体信号。
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.022 秒)
